NEUBASE THERAPEUT. DL-,01
NEUBASE THERAPEUT. DL-,01
Share · US64132K2015 · NBSE · A3EHBD (XNCM)
Overview Financial Indicators
No Price
n/a

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
- - - - -2,73 % -0,43 % -99,74 %

Company Profile for NEUBASE THERAPEUT. DL-,01 Share

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Company Data

Name NEUBASE THERAPEUT. DL-,01
Company NeuBase Therapeutics, Inc.
Symbol NBSE
Website https://www.neubasetherapeutics.com
Primary Exchange XNCM Frankfurt
WKN A3EHBD
ISIN US64132K2015
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mr. Todd P. Branning
Country United States of America
Currency EUR
Employees 0,0 T
Address 350 Technology Drive, 15219 Pittsburgh
IPO Date 2004-05-28

ID Changes

Date From To
16.07.2019 OHRP NBSE

Ticker Symbols

Name Symbol
NASDAQ NBSE

More Shares

Investors who NEUBASE THERAPEUT. DL-,01 hold also have the following shares in their portfolio:
IMMSI S.P.A.
IMMSI S.P.A. Share
JOHN DEE. BK 24/29 MTN
JOHN DEE. BK 24/29 MTN Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025